Pharming buys rare disease drug from Novartis for $20m

Pharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis for $20 million up front, plus other payments further down the line.

First effective Ebola treatment a step closer after breakthr...

Clinical trials of four experimental treatments for Ebola in the Congo have been halted early after two of the drugs showed compelling benefits in a breakthrough against the deadly virus.

US senators blast Novartis for Zolgensma data falsification

US politicians have urged the FDA to come down hard on Novartis for failing to disclose manipulated data used in the approval of its $2.1 million spinal muscular atrophy (SMA) gene therapy Zolge

Science sector lauds UK’s visa scheme, but repeats no-deal B...

Bayer boosts cell therapy pipeline with BlueRock acquisition

Bayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes a treatment for Parkinson’s disease.

Astellas pushes non-hormonal menopause drug into phase 3